Lead Product(s) : THR-149
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Atlas Special Opportunities
Deal Size : $22.8 million
Deal Type : Financing
Details : The financing will be used to fund the Phase 2, Part B KALAHARI trial evaluating Oxurion’s THR-149, a bicyclic peptide that selectively inhibits human plasma kallikrein, for treating the up to 50% of patients with diabetic macular edema (DME).
Product Name : THR-149
Product Type : Peptide
Upfront Cash : Undisclosed
April 27, 2023
Lead Product(s) : THR-149
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Atlas Special Opportunities
Deal Size : $22.8 million
Deal Type : Financing
Lead Product(s) : IMCY-0098
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Imcyse Announces Completion of Enrollment in Phase 2 IMPACT Trial of IMCY-0098 for Type 1 Diabetes
Details : IMCY-0098, a synthetic peptide based on insulin, is designed to halt the progression of diabetes by stopping the body’s immune system from attacking beta cells. With early intervention, the pancreas’ ability to produce insulin may be preserved to man...
Product Name : IMCY-0098
Product Type : Peptide
Upfront Cash : Inapplicable
January 03, 2023
Lead Product(s) : IMCY-0098
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IMCY-0098
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Positive interim biomarker Phase 2 IMPACT Type 1 Diabetes Study data support specific immune signature induced by Imotope (IMCY-0098) and effect on potentially pathogenic T cells.
Product Name : IMCY-0098
Product Type : Peptide
Upfront Cash : Inapplicable
January 13, 2022
Lead Product(s) : IMCY-0098
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable